Trial Profile
A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2020
Price :
$35
*
At a glance
- Drugs Vilaprisan (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Endometriosis; Uterine leiomyoma
- Focus Pharmacodynamics
- Sponsors Bayer
- 27 Jun 2020 Results published in the British Journal of Clinical Pharmacology
- 27 Feb 2019 Status changed from active, no longer recruiting to completed.
- 23 Jan 2019 Planned End Date changed from 21 Dec 2018 to 23 Jan 2019.